医学
骨质疏松症
危险系数
质子抑制剂泵
内科学
置信区间
队列研究
药方
药物流行病学
髋部骨折
前瞻性队列研究
埃索美拉唑
药理学
作者
Mariëlle M. C. van der Hoorn,S. E. Tett,Oscar J. de Vries,Annette J. Dobson,Geeske Peeters
出处
期刊:Bone
[Elsevier]
日期:2015-12-01
卷期号:81: 675-682
被引量:62
标识
DOI:10.1016/j.bone.2015.08.024
摘要
Proton pump inhibitors (PPIs) are among the most prescribed medications worldwide, however, there is growing concern regarding potential negative effects on bone health. The aim was to examine the effect of dose and type of PPI use on subsequent use of osteoporosis medication and fractures in older Australian women. Data were included from 4432 participants (born 1921–26) in the 2002 survey of the Australian Longitudinal Study on Women's Health. Medication data were from the national pharmaceutical administrative database (2003–2012, inclusive). Fractures were sourced from linked hospital datasets available for four major States of Australia. Competing risk regression models used PPI exposure as a time-dependent covariate and either time to first osteoporosis medication prescription or fracture as the outcome, with death as a competing risk. Of the 2328 PPI users and 2104 PPI non-users, 827 (36%) and 550 (26%) became users of osteoporosis medication, respectively. PPI use was associated with an increased risk of subsequent use of osteoporosis medication (adjusted sub-hazard ratio [SHR] = 1.28; 95% confidence interval [CI] = 1.13–1.44) and subsequent fracture (SHR = 1.29, CI = 1.08–1.55). Analysis with PPI categorized according to defined daily dose (DDD), showed some evidence for a dose–response effect (osteoporosis medication: <400 DDD: SHR = 1.23, CI = 1.06–1.42 and ≥400 DDD: SHR = 1.39, CI = 1.17–1.65, compared with non-users; SHRs were in the same range for fractures). Esomeprazole was the most common PPI prescribed (22.9%). Analysis by type of PPI use showed an increased subsequent risk for: (1) use of osteoporosis medication for rabeprazole (SHR = 1.51, CI = 1.08–2.10) and esomeprazole (SHR = 1.48, CI = 1.17–1.88); and (2) fractures for rabeprazole (SHR = 2.06, CI = 1.37–3.10). Users of multiple types of PPI also had increased risks for use of osteoporosis medication and fractures. An appropriate benefit/risk assessment should be made when prescribing PPIs, especially for esomeprazole and rabeprazole, as osteoporosis and fracture risks were increased in this cohort of elderly females subsequent to PPI prescription.
科研通智能强力驱动
Strongly Powered by AbleSci AI